Table 1.
Baseline characteristics
| Patient Characteristic | Erlotinib and Fulvestrant (n=67) |
Erlotinib Alone (n=33) |
P value | |
|---|---|---|---|---|
| Median Age (years) (SD) | 68 (11) | 66 (12) | 0.898 | |
| Gender | 0.728 | |||
| Female (%) | 39 (58) | 18 (55) | ||
| Male (%) | 28 (42) | 15 (45) | ||
| Ethnicity | 0.615 | |||
| Asian (%) | 17 (25) | 7 (21) | ||
| Black (%) | 3 (4) | 2 (6) | ||
| Hispanic (%) | 5 (7) | 5 (15) | ||
| White (%) | 42 (63) | 19 (58) | ||
| Missing (%) | 0 (0) | 0 (0) | ||
| ECOG | 0.787 | |||
| 0 (%) | 27 (40) | 13 (39) | ||
| 1 (%) | 33 (49) | 15 (45) | ||
| 2 (%) | 7 (10) | 5 (15) | ||
| Smoking Status | 0.619 | |||
| Yes (%) | 49 (74) | 26 (79) | ||
| No (%) | 17 (26) | 7 (21) | ||
| Missing (%) | 1 (1) | 0 (0) | ||
| EGFR | 0.119 | |||
| Mutant (%) | 10 (15) | 7 (21) | ||
| Wild Type (%) | 39 (58) | 12 (36) | ||
| Not done (%) | 18 (27) | 14 (43) | ||
| Histology | 0.931 | |||
| Adenocarcinoma (%) | 41 (61) | 21 (64) | ||
| Squamous (%) | 13 (19) | 6 (18) | ||
| Other (%) | 3 (4) | 2 (6) | ||
| Missing (%) | 10 (15) | 4 (12) | ||
| Stage at Enrollment | 0.095 | |||
| IIIB (%) | 10 (15) | 1 (3) | ||
| IV (%) | 57 (85) | 32 (97) | ||
| Number of Prior Treatments for Stage IV | 0.574 | |||
| 0 (%) | 29 (43) | 11 (33) | ||
| 1 (%) | 21 (31) | 10 (30) | ||
| 2 (%) | 11 (16) | 7 (21) | ||
| 3 (%) | 2 (3) | 2 (6) | ||
| 4 (%) | 2 (3) | 0 (0) | ||
| Missing (%) | 2 (3) | 3 (9) | ||
| Cycles Completed (Mean) (SD) | 5.1 (7.2) | 4.4 (7.2) | 0.646 | |